{"id":"NCT02412878","sponsor":"Amgen","briefTitle":"Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma","officialTitle":"A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-09","primaryCompletion":"2017-06-15","completion":"2019-01-07","firstPosted":"2015-04-09","resultsPosted":"2018-12-13","lastUpdate":"2022-09-23"},"enrollment":478,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Carfilzomib","otherNames":["PR-171","PR171","Kyprolis® (carfilzomib) for Injection"]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone","type":"EXPERIMENTAL"},{"label":"Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).","primaryOutcome":{"measure":"Progression Free Survival","timeFrame":"From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.","effectByArm":[{"arm":"Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone","deltaMin":7.6,"sd":null},{"arm":"Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone","deltaMin":11.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0014"},{"comp":"OG000 vs OG001","p":"0.0033"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":140,"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Italy","Japan","New Zealand","Norway","Poland","Romania","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["29866475","33166401","32152297","32108443","31092895","32249621","31388932"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":102,"n":235},"commonTop":["Anaemia","Hypertension","Diarrhoea","Fatigue","Pyrexia"]}}